RAC.AX Racura Oncology Ltd Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
03:19
Jan 17
Jan 17
RAC's Myc inhibitor bisantrene, derisked, buyout candidates circling
The author bought Race Oncology because its reformulated e,e-bisantrene was found to work via Myc inhibition through G4 binding, making it effectively the only Myc inhibitor in the clinical pipeline, and the prior approved use of bisantrene for AML significantly de-risks safety. Stated catalysts include a current phase 3 bridging study in AML with FDA orphan drug designation, early ctDNA/RNA-based clinical validation of Myc inhibition possibly from existing trial data, a just-starting non-small cell lung cancer trial, and potential use as a cardioprotective alongside chemo or with tyrosine kinase inhibitors to prevent TKI resistance. The investment thesis is a bidding war among big pharmas facing patent expiries, supported by the CEO being the largest shareholder and recently buying on market, with Merck's ~US$32bn approach for Revolution Medicines cited as a valuation comparable. The author notes the company may be circumspect about validation data because it does not yet have composition of matter patents.
HIGH
About RAC.AX Investor Commentary
Across the available history and selected sources, Buzzberg tracks RAC.AX (Racura Oncology Ltd) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/lbreav.